Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.

Embodiments described herein provide for uses of grape products, such as Chardonnay grape products and grape seed flour, for use in promoting a healthy liver, promoting healthy fat content in a liver, for treating or preventing NAFLD, and other embodiments and uses as described herein.

Compositions comprising melatonin or derivatives thereof for administration to the epithelium of the lower airway to protect against lung damage due to chest irradiation and/or cytotoxic chemotherapy are provided.

The present invention provides an antioxidant, an ROS inhibitor, an antioxidant enzyme production promoter, an antioxidant cosmetic, a UV care cosmetic, a prophylactic or therapeutic agent for gastrointestinal tract inflammation, and an antioxidant food or beverage, each containing an enzymatically synthesized glycogen (ESG) or an α-amylase digest (RG) thereof, as well as use for enhancing an antioxidative effect in vivo.

The subject invention relates to novel micoparticulate and soluble forms of flavonoids, and their synthesis. The invention also includes novel formulations of such flavonoids. Further, the invention includes novel methods of manufacturing the flavonoid formulations. The invention also relates to a wide variety of applications of the flavonoid formulations.

The present invention relates generally to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7, 8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide, polymorphic forms thereof, methods for preparation and use thereof, pharmaceutical compositions thereof, and kits and articles of manufacture thereof.

Compounds may be administered to prevent or rescue organ injury following exposure to alkylating agents, such as sulfur mustards. The compounds may be substituted metalloporphyrins.

The Present invention provides a novel pyrazole derivative compound represented by Chemical formula 1, a stereoisomer thereof, a solvate thereof, an isotopic variant thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.

##STR00001##

(In the above, A, B and R, and the like are the same as defined in the description of the invention.)

The Present invention provides a novel pyrazole derivative compound represented by Chemical formula 1, a stereoisomer thereof, a solvate thereof, an isotopic variant thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.

##STR00001##

(In the above, A, B and R, and the like are the same as defined in the description of the invention.)

The invention discloses a cannabinoid nano-micelle preparation and a preparation method thereof. The cannabinoid nano-micelle preparation includes cannabinoid and an amphiphilic polymer, wherein the content of the cannabinoid is 1-40% by weight, the content of the amphiphilic polymer is 1-99%, and the preparation method includes the following steps: (1) preparing a cannabinoid nano-micelle solution from cannabinoid and an amphiphilic polymer; (2) drying the micellar solution obtained in the step (1) to obtain cannabinoid nano-micelle powder; and (3) preparing the cannabinoid nano-micelle powder obtained in the step (2) into the cannabinoid nano-micelle preparation. The cannabinoid nano-micelle preparation is high in effective component wrapping rate and transfer rate, high in drug loading capacity and high in stability, and a novel normal-temperature self-assembly technology is adopted, so that an active component cannabinoid is prevented from being degraded and discolored at high temperature; the bioavailability of the active ingredient is high, and a single dose can be reduced. Especially, a dry powder inhalant is high in in-vitro deposition rate and quick in inhalation effect, and can provide continuous and stable blood concentration.